Synergy Pharmaceuticals Appoints Patrick H. Griffin, M.D. as Chief Medical Officer
5/30/2013 10:08:40 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEW YORK, May 29, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the appointment of Patrick H. Griffin, M. D., FACP as Chief Medical Officer. Dr. Griffin will report directly to President and Chief Executive Officer, Gary S. Jacob, Ph.D., and will be responsible for guiding Synergy's clinical programs, particularly the plecanatide Phase III program on chronic idiopathic constipation (CIC), and the ongoing Phase IIb trial of plecanatide in irritable bowel syndrome with constipation (IBS-C).
Help employers find you! Check out all the jobs and post your resume.
comments powered by